Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Divarasib alone or with pembrolizumab-based therapy in previously untreated KRAS G12C-mutant advanced non-small cell lung cancer
2023-507171-22-00Phase 2Authorised
- Sponsor
- Roche
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 2, open-label trial of divarasib in non-small cell lung cancer (NSCLC) (4 cohorts), sponsored by Roche. Primary endpoints: Occurrence of adverse events and Change from baseline in targeted safety parameters. Planned start Jun 2023; status: authorised.
02
Drugs
divarasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-507171-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507171-22-00.